Welcome to our dedicated page for Centene Del SEC filings (Ticker: CNC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Centene Corporation (NYSE: CNC) SEC filings, offering insight into the company’s regulatory disclosures, financial communications, and governance updates. As a healthcare enterprise focused on government-sponsored and commercial healthcare programs, Centene uses filings such as Form 8-K to inform investors about material events, earnings information, and board changes.
Recent 8-K filings describe Centene’s participation in healthcare investor conferences, where management discusses the company’s financial outlook and the use of non-GAAP financial measures like adjusted diluted earnings per share. Other 8-Ks report quarterly financial results, the withdrawal or update of earnings guidance, and the resignation of directors along with resulting changes in the size of the board. These documents help investors understand how Centene evaluates its performance, plans operations, and manages corporate governance.
Through this filings page, users can review Centene’s current and historical submissions to the U.S. Securities and Exchange Commission, including annual and quarterly reports when available, as well as event-driven filings. Real-time updates from EDGAR are combined with AI-powered summaries that explain the key points of complex documents, helping readers interpret financial metrics, non-GAAP reconciliations, and narrative disclosures without wading through every page.
In addition to financial information, Centene’s filings may address topics such as regulatory considerations, risk factors related to government healthcare programs, and the company’s approach to non-GAAP reporting. For investors tracking CNC, this page serves as a central location to monitor new filings, understand the context of earnings announcements, and follow changes in leadership or guidance as they are formally reported to the SEC.
Centene Corp’s Corporate Controller and Chief Accounting Officer reported a new stock award and corrected prior holdings. On 01/26/2026, the officer acquired 26,036 shares of Centene common stock at $0 as equity compensation, bringing beneficial ownership to 113,135 shares held directly.
The award consists of 13,018 restricted stock units that vest in three annual installments beginning on March 15, 2027, and 13,018 performance stock units reported at target. The performance stock units are scheduled to vest on March 15, 2029, with the actual number ranging from 0% to 200% of target based on Centene’s stock price performance for the final 20 trading days of 2025 compared to the final 60 trading days of 2028. The amendment also removes 9,236 shares from total holdings, reflecting performance stock units for the period ending December 31, 2025 that did not meet vesting criteria as determined on January 26, 2026.
Centene Corp’s Chief People Officer reported an equity award of 74,311 shares of common stock at $0 per share. After this grant, the officer beneficially owns 131,007 shares directly.
The new award includes 29,724 restricted stock units that vest in three annual installments beginning on March 15, 2027, plus 44,587 performance stock units reported at target. The performance units can vest from 0% to 200% of target on March 15, 2029, based on Centene’s stock price performance over specified trading periods in 2025 and 2028. This amended filing removes 2,073 previously counted performance stock units that did not meet vesting criteria, and notes that current ownership also includes 47,267 previously granted restricted and performance stock units subject to vesting.
Centene Corporation’s chief operating officer reported an amended equity award on Form 4/A. On January 26, 2026, the officer received 112,823 shares of common stock at $0, lifting direct beneficial ownership to 215,638 shares.
The award includes 45,129 restricted stock units that vest in three annual installments beginning March 15, 2027, plus 67,694 performance stock units at target. Those performance units can vest between 0% and 200% on March 15, 2029 based on Centene’s stock price performance over specified 2025 and 2028 trading periods. The amendment removes 9,651 unvested performance units that did not meet vesting criteria, and ownership also reflects 80,466 previously granted restricted and performance units still subject to vesting.
Centene Corporation’s secretary and general counsel, Christopher A. Koster, reported an award of 126,925 shares of common stock at a price of $0, increasing his directly held beneficial ownership to 361,922.617 shares.
The grant consists of 50,770 restricted stock units that vest in three annual installments beginning on March 15, 2027, and 76,155 performance stock units reported at target. The performance units can vest at 0%–200% of target on March 15, 2029 based on the company’s stock price performance over specified trading-day windows in 2025 and 2028.
The amendment also updates Koster’s holdings to remove 26,939 shares tied to performance stock units for the period ending December 31, 2025 that did not meet vesting criteria, as determined on January 26, 2026. Current ownership includes 123,574 previously granted stock units that remain subject to vesting requirements.
Centene Corporation’s chief financial officer reported a new equity grant and corrected prior holdings. On 01/26/2026, the CFO acquired 173,573 shares of common stock at a price of $0, bringing beneficial ownership to 763,230.48 shares held directly.
The award includes 69,429 restricted stock units vesting in three annual installments beginning on March 15, 2027, plus 104,144 performance stock units at target that may vest on March 15, 2029, from 0% to 200% of target based on stock price performance tests. The amendment removes 67,985 performance stock units from total holdings because they did not meet vesting criteria for the performance period ending December 31, 2025, as determined by the Compensation and Talent Committee on January 26, 2026. Current ownership also includes 316,262 previously granted restricted and performance stock units subject to vesting.
Centene Corporation reported that its Chief Executive Officer received an equity award covering 520,720 shares of common stock at a price of $0. After this grant, the CEO beneficially owns 1,224,892 shares.
The award includes 138,859 restricted stock units vesting in three annual installments starting March 15, 2027, and 69,429 restricted stock units vesting in five annual installments starting the same date. It also includes 312,432 performance stock units at target, which can vest at 0% to 200% of this amount on March 15, 2029, based on stock price performance tests. The amendment removes 141,103 previously reported performance stock units that failed to meet vesting criteria, and ownership continues to reflect 450,895 previously granted restricted and performance stock units subject to vesting.
Centene Corporation reported strong 2025 growth in revenue but a large accounting loss and issued 2026 guidance. Total 2025 revenues were $194.8 billion, with premium and service revenues of $174.6 billion, up 20% from 2024.
The company recorded a GAAP diluted loss per share of $(13.53), mainly from a non‑cash $6.7 billion goodwill impairment and a $513 million Magellan Health impairment. On an adjusted basis, diluted EPS was $2.08. The full‑year health benefits ratio rose to 91.9% from 88.3%, reflecting higher medical costs, while the adjusted SG&A expense ratio improved to 7.4% from 8.5%.
Cash flow provided by operations reached $5.1 billion, and cash, investments and restricted deposits totaled $38.8 billion at year end. For 2026, Centene guides to adjusted diluted EPS greater than $3.00, total revenues of $186.5–$190.5 billion, and a projected HBR of 90.9%–91.7%, implying margin recovery efforts alongside continued growth.
Centene Corporation’s Chief Operating Officer, Susan Raye Smith, received an equity award of 112,823 shares of common stock on January 26, 2026. The grant was reported at a price of $0 per share and increased her beneficial ownership to 225,289 shares.
The award consists of 45,129 restricted stock units that vest in three annual installments beginning March 15, 2027, and 67,694 performance stock units reported at target. The performance stock units are scheduled to vest on March 15, 2029, with the actual number earned ranging from 0% to 200% of the target amount, based on Centene’s stock price performance between the final 20 trading days of 2025 and the final 60 trading days of 2028. Her total includes 90,117 previously granted restricted and performance stock units that remain subject to vesting requirements.
Centene Corporation granted Chief People Officer Tanya M. McNally 74,311 shares of common stock as equity compensation on January 26, 2026 at a price of $0 per share. Following this award, she beneficially owns 133,080 shares directly.
The new grant consists of 29,724 restricted stock units that vest in three annual installments beginning on March 15, 2027, and 44,587 performance stock units reported at target. The performance stock units can vest from 0% to 200% of target on March 15, 2029 based on Centene’s stock price performance over specified trading-day periods in 2025 and 2028. Existing ownership also includes 49,340 previously granted restricted and performance stock units that remain subject to vesting.
Centene Corporation CEO Sarah London received a large equity grant reported on January 26, 2026. She was awarded 520,720 shares of Centene common stock at a grant price of $0, bringing her directly owned common stock to 1,365,995 shares.
The award includes 138,859 restricted stock units vesting in three annual installments beginning March 15, 2027, and 69,429 restricted stock units vesting in five annual installments beginning the same date. It also includes 312,432 performance stock units at target; the actual amount vesting on March 15, 2029 can range from 0% to 200% of that target based on Centene’s stock price performance over specified trading-day periods in 2025 and 2028.
Her ownership also reflects 591,998 previously granted restricted and performance stock units that remain subject to vesting. In addition, she directly holds a performance stock option for 13,449 shares at an exercise price of $81.85 per share, expiring December 15, 2031, which may become exercisable if Centene’s stock trades at or above $100 for 20 consecutive trading days after the original grant date.